Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
56 hedge funds and large institutions have $215M invested in Five Prime Therapeutics, Inc. in 2014 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 25 increasing their positions, 7 reducing their positions, and 4 closing their positions.
375% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 4
257% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 7
68% more capital invested
Capital invested by funds: $128M → $215M (+$87.2M)
33% more funds holding
Funds holding: 42 → 56 (+14)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$18.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$15.9M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$11.5M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$8.71M |
| 5 |
Millennium Management
New York
|
+$5.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$13.3M |
| 2 |
WT
Wellcome Trust
London,
United Kingdom
|
-$2.64M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.14M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$760K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$428K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of Montreal
Toronto,
Ontario, Canada
| $20K | – | – | – |
|
52
Barclays
London,
United Kingdom
| $7K | +$4.82K | +284 | +312% |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| $1K | +$1.02K | +60 | New |
|
54
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $41 | +$33.2K | +1,957 | +1,517% |
|
|
55
Alyeska Investment Group
Chicago,
Illinois
| – | -$2.14M | -127,401 | Closed |
|
|
WSA
56
Wall Street Associates
Lajolla,
California
| – | -$420K | -25,000 | Closed |
|
|
CAM
57
Cormorant Asset Management
Boston,
Massachusetts
| – | -$336K | -20,000 | Closed |
|
|
SO
58
STRS Ohio
Columbus,
Ohio
| – | -$39.1K | -2,300 | Closed |
|
59
Ameriprise
Minneapolis,
Minnesota
| – | +$170 | +10 | New |
|
60
Bank of America
Charlotte,
North Carolina
| – | +$221 | +13 | New |
|
FPRX Hedge Fund Activity: Q1 2014 in Review
56 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q1 2014, worth a combined $215M — up 68% from $128M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new FPRX positions and 4 closed out — a net gain of 15 holders — while 25 added to existing stakes and 7 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $18.3M. The largest seller was HealthCor Management, cutting an estimated $13.3M.
- 56 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q1 2014, up from 42 in Q4 2013.
- Funds reported $215M of Five Prime Therapeutics, Inc. stock for Q1 2014, up 68% quarter-over-quarter.
- 19 funds opened new Five Prime Therapeutics, Inc. positions in Q1 2014 and 4 closed out, a net change of +15 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q1 2014 was OrbiMed, an estimated $18.3M added.
- The largest Five Prime Therapeutics, Inc. seller in Q1 2014 was HealthCor Management, an estimated $13.3M sold.
Based on aggregated 13F filings for Q1 2014.